iBio
IBIO
13 hedge funds and large institutions have $184K invested in iBio in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
33% less capital invested
Capital invested by funds: $275K → $184K (-$91K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$20.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.87K |
| 3 |
VF
Virtu Financial
New York
|
+$774 |
| 4 |
BlackRock
New York
|
+$387 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$49.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 3 |
S
SignatureFD
Atlanta,
Georgia
|
-$13K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$5.42K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$2.71K |
IBIO Hedge Fund Activity: Q4 2018 in Review
13 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2018, worth a combined $184K — down 33% from $275K a quarter earlier.
Fund positioning in IBIO was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.5K. The largest seller was Vanguard Group, cutting an estimated $49.5K.
- 13 institutional investors held iBio (IBIO) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $184K of iBio stock for Q4 2018, down 33% quarter-over-quarter.
- 3 funds opened new iBio positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest iBio buyer in Q4 2018 was Citadel Advisors, an estimated $20.5K added.
- The largest iBio seller in Q4 2018 was Vanguard Group, an estimated $49.5K sold.
Based on aggregated 13F filings for Q4 2018.